Una vacuna pentavalente recombinante frente a S Aureus ha mostrado ser segura e inmunógena en la Fase II
Jiang X, Gong M, Zhang H et al. The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial. Vaccine 2023;41:5562-5571 https://www.sciencedirect.com/science/article/abs/pii/S0264410X23008782 Fase II de un ensayo clínico aleatorio, doble ciego y controlado con placebo para evaluar la…
Detalles